- document
-
Hettne, K.M. (author), Boorsma, A. (author), van Dartel, D.A.M. (author), Goeman, J.J. (author), de Jong, E. (author), Piersma, A.H. (author), Stierum, R.H. (author), Kleinjans, J.C. (author), Kors, J.A. (author)Background: Availability of chemical response-specific lists of genes (gene sets) for pharmacological and/or toxic effect prediction for compounds is limited. We hypothesize that more gene sets can be created by next-generation text mining (next-gen TM), and that these can be used with gene set analysis (GSA) methods for chemical treatment...article 2013
- document
-
Clare, M.G. (author), Lorenzon, G. (author), Akhurst, L.C. (author), Marzin, D. (author), van Delft, J. (author), Montero, R. (author), Botta, A. (author), Bertens, A. (author), Cinelli, S. (author), Thybaud, V. (author), Lorge, E. (author), TNO Kwaliteit van Leven (author)This study on the in vitro micronucleus assay, comprising 11 laboratories using human lymphocytes, was coordinated by an organizing committee supported by the SFTG (the French branch of the European Environmental Mutagen Society). Nine coded substances were assessed for their ability to induce micronuclei in human lymphocytes in vitro, mitomycin...article 2006
- document
-
Kleemann, R. (author), Gervois, P.P. (author), Verschuren, L. (author), Staels, B. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)C-reactive protein (CRP) is a major acute-phase protein in humans. Elevated plasma CRP levels are a risk factor for cardiovascular disease. CRP is predominantly expressed in hepatocytes and is induced by interleukin-1 (IL-1) and IL-6 under inflammatory situations, such as the acute phase. Fibrates are hypolipidemic drugs that act through the...article 2003
- document
-
Post, S.M. (author), Duez, H. (author), Gervois, P.P. (author), Staels, B. (author), Kuipers, F. (author), Princen, H.M.G. (author), Gaubius Instituut TNO (author)Fibrates are hypolipidemic drugs that affect the expression of genes involved in lipid metabolism by activating peroxisome proliferator-activated receptors (PPARs). Fibrate treatment causes adverse changes in biliary lipid composition and decreases bile acid excretion, leading to an increased incidence of cholesterol gallstones. In this study,...article 2001
- document
-
Lake, B.G. (author), Rumsby, P.C. (author), Price, R.J. (author), Cunninghame, M.E. (author), TNO BIBRA TNO Kwaliteit van Leven (author)The objective of this study was to evaluate species differences in the hepatic effects of three potent rodent peroxisome proliferators, namely methylclofenapate (MCP), ciprofibrate (CIP) and Wy-14,643 (WY), particularly with respect to effects on replicative DNA synthesis and transforming growth factor-β1 (TGF-β1) gene expression. Male Sprague...article 2000
- document
-
Kockx, M. (author), Gervois, P.P. (author), Poulain, P. (author), Derudas, B. (author), Peters, J.M. (author), Gonzalez, F.J. (author), Princen, H.M.G. (author), Kooistra, T. (author), Staels, B. (author), Gaubius instituut TNO (author)Plasma fibrinogen levels have been identified as an important risk factor for cardiovascular diseases. Among the few compounds known to lower circulating fibrinogen levels in humans are certain fibrates. We have studied the regulation of fibrinogen gene expression by fibrates in rodents. Treatment of adult male rats with fenofibrate (0.5% [wt/wt...article 1999
- document
-
Kockx, M. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)Fibrates are used to lower plasma triglycerides and cholesterol levels in hyperlipidemic patients. In addition, fibrates have been found to alter the plasma concentrations of fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and apolipoprotein A-I (apo A-I). We have investigated the in vitro effects of fibrates on fibrinogen, PAI-1 and apo A...article 1998
- document
-
de Maat, M.P.M. (author), Knipscheer, H.C. (author), Kastelein, J.J.P. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)An elevated plasma fibrinogen level is increasingly accepted as an independent risk indicator of cardiovascular disease. This has enhanced the interest in identifying agents that can normalize elevated plasma fibrinogen levels. One group of agents with this capacity are the fibric acid derivatives, e. g. ciprofibrate and gemfibrozil. We studied...article 1997
- document
-
Kockx, M. (author), de Maat, M.P.M. (author), Knipscheer, H.C. (author), Kastelein, J.P. (author), Kluft, C. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)Evaluation of fibrate treatment in humans has focused primarily on its anti-lipidaemic effects. A potentially favourable haemostasis-modulating activity of fibrates has also been recognized but the data are not consistent. We sought to learn more about this variability by examining the effects of gemfibrozil and ciprofibrate on plasma levels of...article 1997
- document
-
Brommer, E.J.P. (author), Leuven, J.A.G. (author), Barrett-Bergshoeff, M.M. (author), Schouten, J.A. (author), Gaubius instituut TNO (author)Impairment of fibrinolysis is supposed to contribute to CVD. In 38 hyperlipoproteinemic patients, known to be at risk for early CVD, fibrinolytic activity was measured before and after stimulation with DDAVP. A negative correlation was found between serum triglyceride levels and fibrinolytic activity, both before and after DDAVP. A subnormal...article 1982